专利简介

A SARS-CoV-2 nucleocapsid protein-specific vNAR isolated from a naïve phage library

简介
This application relates to a vNAR, which is isolated from a naïve phage library and is SARS-CoV-2 nucleocapsid protein-specific.As shark vNAR (variable domain of the new antigen receptor) has emerged as an uprising star in novel antibody-based therapies, multiple studies have reported their vNAR with potential disease treatment functions, such as treating the tumour, malaria, CoV-ID19, Ebola hemorrhagic fever, CNS diseases, and inflammation. While these vNARs were generated from immunized shark vNAR libraries, in which the immunization process causes about 6 months and requires long-term animal maintenance. Thus, there is a need to develop a naïve library without the immunization process, which can be used for selecting multiple antigens for future needs.

简介

This application relates to a vNAR, which is isolated from a naïve phage library and is SARS-CoV-2 nucleocapsid protein-specific.As shark vNAR (variable domain of the new antigen receptor) has emerged as an uprising star in novel antibody-based therapies, multiple studies have reported their vNAR with potential disease treatment functions, such as treating the tumour, malaria, CoV-ID19, Ebola hemorrhagic fever, CNS diseases, and inflammation. While these vNARs were generated from immunized shark vNAR libraries, in which the immunization process causes about 6 months and requires long-term animal maintenance. Thus, there is a need to develop a naïve library without the immunization process, which can be used for selecting multiple antigens for future needs.